08:00 , Dec 19, 2011 |  BC Week In Review  |  Clinical News

Elucigene FH20 regulatory update

The U.K.'s NICE issued final guidance recommending against the use of the genetic tests Elucigene FH20 from Gen-Probe and LIPOchip from Progenika Biopharma S.A. (Derio, Spain) to confirm a clinical diagnosis of familial hypercholesterolemia (...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Clinical News

LIPOchip regulatory update

The U.K.'s NICE issued final guidance recommending against the use of the genetic tests Elucigene FH20 from Gen-Probe Inc. (NASDAQ:GPRO, San Diego, Calif.) and LIPOchip from Progenika Biopharma to confirm a clinical diagnosis of familial...
07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Few Cinderellas this time

Big caps suffered the least in a very ugly quarter. But that's not saying much: biotechs with market caps of more than $5 billion were still down 10% as a group in 3Q, while other...
07:00 , Sep 26, 2011 |  BioCentury  |  Regulation

NICE's diagnostic tests

NICE 's new program for assessing the cost-effectiveness of diagnostics layers the agency's existing analytical model on top of the diagnostic space. It is unclear whether this process is a good fit. It also is...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Clinical News

Elucigene FH20 regulatory update

The U.K.'s NICE issued draft guidance recommending against the use of the genetic tests Elucigene FH20 from Gen-Probe and LIPOchip from Progenika Biopharma S.A. (Derio, Spain) to confirm a clinical diagnosis of familial hypercholesterolemia (...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Clinical News

LIPOchip regulatory update

The U.K.'s NICE issued draft guidance recommending against the use of the genetic tests Elucigene FH20 from Gen-Probe Inc. (NASDAQ:GPRO, San Diego, Calif.) and LIPOchip from Progenika Biopharma to confirm a clinical diagnosis of familial...
07:00 , Aug 1, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Affymax Inc. (NASDAQ:AFFY) lost $0.64 to $6.61 last week after FDA accepted for review an NDA for peginesatide (formerly Hematide ) to treat anemia in chronic kidney disease (CKD) patients on dialysis. Affymax...
23:39 , Jul 25, 2011 |  BC Extra  |  Company News

NICE recommends against FH genetic tests

The U.K.'s NICE issued draft guidance recommending against the use of the genetic tests Elucigene FH20 from Gen-Probe Inc. (NASDAQ:GPRO) and LIPOchip from Progenika Biopharma S.A. (Derio, Spain) to confirm a clinical diagnosis of familial...
07:00 , Sep 1, 2008 |  BC Week In Review  |  Company News

Tepnel sales and marketing update

Tepnel launched its Elucigene FH20 kit in the U.K. for early detection of familial hypercholesterolemia (FH). The in vitro genotyping assay for 20 genetic mutations in the U.K.-based population received CE Mark approval in August....